Overall costs of radiation therapy for early-stage breast cancer do not burden the health care system when analyzed in relation to survival benefit. READ MORE

News

By Marilynn Larkin

NEW YORK (Reuters Health) – In women with breast cancer, zoledronic acid taken every three months is more cost-effective for reducing the risk of skeletal-related events than monthly zoledronic acid or monthly denosumab, researchers say.

READ MORE

Patients with breast cancer who take opioids to manage their pain are less likely to adhere to adjuvant therapy, resulting in a higher risk of death.

READ MORE